Vertex Pharmaceuticals Incorporated

VRTX · Healthcare

$510.08
+1.36% today

What a holder would want to know before buying VRTX: where the price sits in its own history, how far it has fallen before and whether it recovered, and what the business behind it earns. All of it is arithmetic over free market data — no opinions, no recommendations.

Where the price sits
Low $407.37 · Oct 2025High $557.96 · Sep 2026

Today’s price is 25% above the lowest point of the past year and 9% below the highest.

Over the past year it was cheaper than today on 85% of days and more expensive on 15%. Over the last 10 years: cheaper on 98% of days.

7% above its average price of the last 200 trading days.

How bad does it get

Fell 20% or more 4 times in 10 years. The deepest fall was 42%; the longest took 2.1 years to get back to its peak. Every one recovered.

Now 9% below the Sep 2026 peak.

Nov 2024
−29%back in 20 months
Jul 2020
−42%back in 2.1 years
Sep 2018
−21%back in 4 months
Aug 2016
−30%back in 8 months
What you own

Vertex Pharmaceuticals Incorporated · Healthcare · Biotechnology · a large company worth $129.29B

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on…

Is it making money?
2022
2023
2024
2025

revenue profit

Sales of $12.00B in 2025, with $3.95B of profit. Sales grew in 3 of the last 3 years.

Keeps about 35 cents of every dollar of sales as profit.

Is it healthy?
Cash
$7.85B
Debt
$1.98B
Free cash flow / yr
$2.63B

Generates more free cash in a year ($2.63B) than it owes in total ($1.98B).

Is it expensive?

You pay $30 for every $1 of last year’s profit, and $25 for every $1 of profit expected next year.

A high number means buyers expect growth; a low one means they expect little, or fear trouble. Large US companies have averaged roughly 15–20 over the decades.

Pays no dividend.

What others are doing

32 analysts: 26 say buy, 5 hold, 1 sell. Their average 12-month target is $571.61 (range $350.00–$672.00).

Insiders made 0 purchases and 14 sales in the last 6 months. Executives routinely sell shares they were paid in; buying with their own money is the rarer signal.

Free data from Yahoo Finance, refreshed daily. This is evidence about the business and its price history, not a recommendation.

Now try it without risking anything

Poshkan is paper trading: real prices, virtual money. Buy VRTX with $10,000 that isn’t real, set a stop before you enter, and find out what your idea would actually have done.

Data from Yahoo Finance, refreshed hourly. Nothing here is financial advice. Poshkan is a paper-trading simulator — all money, trades and returns are virtual.